Background: Increased focus has been placed on perioperative and long-term outcomes in the treatment of peripheral artery disease (PAD), both for purposes of quality improvement and for assessment of performance at a surgeon and institutional level. This study evaluates regional variation in outcomes after treatment for PAD within the Vascular Quality Initiative (VQI). By describing the variation in practice patterns and outcomes across regions, we hope that each regionally based quality group can select which areas are most important for them to focus on as they will have access to their regional data to compare.
ever, as complications following surgical care are poorly defined. Early studies on regional variation in mortality rates suggested that variation was not due to case mix alone but included numerous other patient and provider factors. [2] [3] [4] Since these early studies highlighting the variation that exists, there have been multiple efforts to reduce variation in outcomes. Such efforts include selective referral initiatives, pay-for-performance programs, and pay-for-participation clinical registries. Despite the good intentions of such programs, a full understanding of the variation in surgical practice and its causes remains unknown. Birkmeyer and Dimick have suggested that variation in surgical mortality is not synonymous with quality of care but also comes from chance and case mix. 5 Compounding the difficulty of identifying the cause of variation in outcomes are the methods used for calculation of an adverse outcome rate. Before The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest.
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http://dx.doi.org/10.1016/j.jvs.2017.01.061 this, Iezonni introduced the "algebra of effectiveness," which stated that patient outcomes resulted from patient factors, effectiveness of care delivered, and random effects. 6 The Centers for Medicare & Medicaid Services established a list of Physician Quality Reporting System measures to judge quality that (for now) focus on 1-year adverse limb and patient events in those with claudication, in whom event rates should be low. 7 For chronic limb-threatening ischemia (CLI), disease severity and variability of clinical status at presentation have made it difficult to define benchmark rates of adverse events; but in creating end point targets for the comparison of catheter-based treatments to bypass, the Society for Vascular Surgery (SVS) has provided meaningful targets for comparison in CLI as well. 8 Both these measures analyze outcomes in an unadjusted but stratified manner. A threatened limb classification to stratify risk of amputation based on the status of the limb at presentation has been published by the SVS, and wound, ischemia, and foot infection variables are being incorporated into the Vascular Quality Initiative (VQI), but VQI outcomes data using this classification system are not yet available. 9 In this study, we examine the variation in outcomes following lower extremity revascularization across the regions of the SVS VQI, a national clinical vascular registry. This is a follow-up to our initial study evaluating variation in patient selection, treatment type, and process measures for lower extremity vascular disease across the same population. 10 In this manuscript, we focus on perioperative and select long-term outcomes after lower extremity intervention, including those in the Table. This report is meant to serve as a description of current outcomes related to the treatment of peripheral artery disease (PAD), and we hope it will serve as a tool for future quality improvement projects.
METHODS
Data set. The VQI database was used to identify all infrainguinal open and endovascular operations from participating hospitals across the United States from 2009 to 2014. The VQI is a national clinical registry, set up as collaboration between regional quality groups, as described previously. 10 More information about the VQI can be found at www.vascularqualityinitiative.org. The Institutional Review Board at Beth Israel Deaconess Medical Center approved this study and informed consent was waived.
Cohorts and variables. All 16 regions were included in the analysis, and each region had >100 surgical bypasses and 100 lower extremity endovascular interventions. Outcomes were stratified by symptom status and procedure type. All endovascular procedures consisting of isolated suprainguinal interventions were excluded (n ¼ 13,560). Patients presenting with acute limb ischemia were analyzed separately (n ¼ 5400). Outcomes were evaluated at perioperative (in-hospital and 30-day) and 1-year time points. Patients were defined as eligible for 1-year follow-up if their operative date occurred 9 months or more before the date of our data extraction (August 1, 2014). All procedures were used to determine perioperative outcomes, but only a patient's initial endovascular and bypass procedures were used to evaluate 1-year events. This excluded 23% of endovascular cases and 10% of bypasses that were secondary.
Renal deterioration was defined as serum creatinine concentration increase >0.5 mg/dL or new dialysis. A technically unsuccessful endovascular intervention was defined as residual stenosis >30% or failure to cross a lesion in any treated lesion. Hematoma was defined as either minor or needing transfusion or reoperation. Intraprocedural endovascular complication included dissection, perforation, and embolization. These definitions are defined by the VQI registry, and many cannot be modified. Primary patency was defined as a patent treated vessel at time of discharge without the need for additional interventions. The SVS objective performance goals (OPGs) define clinically high risk patients as age >80 years with tissue loss for stratification purposes, which we employ for this analysis. 8 Statistical analysis. All perioperative outcomes reported were in-hospital events with the exception of 30-day mortality and perioperative death, defined as in-hospital or 30-day mortality, and were compared using c 2 analysis, with P value < .05 considered significant, which highlights that there was a significant difference across the range of regional values. One-year analysis was performed only for variables with reliable dates of event, using KaplanMeier time to event analysis, with significance determined by the log-rank test. Regions with inadequate 1-year followup data, defined as a standard error >0.10, were excluded from 1-year analysis, which excluded one region for survival and amputation-free survival (AFS) analysis. All perioperative end points discussed had <5% missing data. There were minimal regional differences for proportion of missing data for perioperative end points, with all regions having <5% missing data for all end points with the exception of two regions having 10% and 15% missing data 
Recommendation:
The authors recommend decreasing regional variation to improve outcomes after infrainguinal revascularization.
on rates of dissection, perforation, or embolization after endovascular intervention. Survival data in the VQI are supplemented by the Social Security Death Index and are therefore considered complete; however, additional secondary end points are limited by incomplete followup data, and therefore we evaluated only AFS in addition to survival. Furthermore, we performed a subanalysis for AFS using only data from medical centers reporting >50% 1-year follow-up within the VQI. Forest plots and bar charts were used for variables of interest. Each forest plot line illustrates the range among the regions for each variable listed, with the repeating symbols along each line representing an individual region and the perpendicular vertical line representing the regional-level median. Pearson correlation was used to compare the linear relationship between perioperative outcomes of interest. Risk-adjusted perioperative mortality was calculated using previously published risk factors for mortality after lower extremity revascularization to calculate expected mortality for each patient; included in our logistic regression for expected mortality were age >79 years, insulin-dependent diabetes, coronary artery disease, congestive heart failure, chronic obstructive pulmonary disease, emergent procedure, dialysis dependence, nonindependent ambulatory status, and CLI. 11, 14 An observed to expected ratio for mortality was then standardized to the overall perioperative mortality in the VQI for the same population. All analysis was performed using SPSS version 22.0 (IBM Corp, Armonk, NY).
RESULTS

Perioperative outcomes
Demographics of patients included in this analysis were reported in part 1. 10 In brief, 16,145 bypasses were included: 5% for asymptomatic PAD (54% of these for aneurysmal disease), 26% for claudication, 56% for CLI (61% of these for tissue loss), and 13% for acute limb ischemia. For endovascular procedures, 35,338 interventions were included: 4% were asymptomatic (19% aneurysmal disease), 40% for claudication, 46% for CLI (73% tissue loss), and 12% for acute limb ischemia. After exclusion of asymptomatic patients, there were a total of 15,338 bypasses and 33,925 endovascular interventions for symptomatic PAD.
Claudication. Procedure volume within each of the 16 regions ranged from 39 to 1649 infrainguinal bypasses for claudication. Thirty-day mortality ranged from 0.0% to 2.6% (P ¼ .37). Significant variation between regions was seen in the proportion of patients receiving >2 units of transfused red blood cells (0.0%-13%; P < .001), surgical site infections (SSIs; 0.0%-9%; P ¼ .001), any return to the operating room (0.9%-9.3%; P ¼ .02), and dysrhythmia (0.0%-7.7%; P ¼ .01; Fig 1) . Notably, there was not significant variation between regions in the rate of ipsilateral in-hospital major amputation (0.0%-0.6%; P ¼ .98), primary patency at discharge (94%-100%; P ¼ .10), renal deterioration (0.0%-5%; P ¼ .30), or postoperative myocardial infarction (0.0%-4%; P ¼ .40).
Lower extremity endovascular intervention procedure volume ranged from 76 to 3219 across regions. Thirtyday mortality was low across all regions and ranged from 0.0% to 0.5% (P ¼ .77). Among patients living at home preoperatively, there was significant variation between regions in the proportion who were not discharged to home (0.5%-5%; P < .001), unplanned admissions (0.7%-3%; P ¼ .045), technically unsuccessful interventions for both multivessel (0.0%-23%; P < .001) and single-vessel interventions (3.3%-15%; P < .001), hematoma rates (1.5%-5%; P < .001), and intraprocedural complications (3.5%-17%; P < .001; Fig 2) .
CLI. Bypass procedure volume ranged from 58 to 3165 across regions for patients with CLI. Thirty-day mortality ranged from 0.0% to 5.0% (P ¼ .08). There was significant variation between regions in proportion of patients receiving >2 units of red blood cells transfused (6.9%-27%; P < .001), SSIs (0.8%-8%; P < .001), dysrhythmia (0.8%-9%; P < .001), and myocardial infarction (0.8%-6%; P ¼ .001; Fig 3) . In addition, for elective cases only (73% of those with CLI), there was significant variation between regions in return to the operating room (0.0%-27%; P < .001), in-hospital ipsilateral major amputation (0.0%-4.3%; P ¼ .004), and primary patency at discharge (84%-98%; P < .001).
Lower extremity endovascular procedure volume for CLI ranged from 136 to 3522 across regions. There was significant variation between regions in 30-day mortality (0.5%-3%; P < .001), and subgroup analysis showed significant variation between regions in patients with tissue loss (0.0%-3%; P < .001) but not rest pain (0.0%-3%; P ¼ .27). There was significant variation between regions in technically unsuccessful interventions for multivessel (8.8%-31%; P < .001) and single-vessel procedures (6.6%-20%; P < .001) and hematoma rates (2.0%-5%; P < .001; Fig 4) . Among elective cases (76% of those with CLI), there was significant variation between regions in proportion of patients not discharged to home (4.0%-16%; P < .001), complication leading to admission (0.9%-4%; P < .001), and intraprocedural complications (3.7%-17%; P < .001). There was no relationship between intraprocedural complication and technically unsuccessful interventions (r ¼ .18; P ¼ .50).
Unadjusted and risk-adjusted perioperative mortality for both endovascular and bypass revascularizations was low across the VQI (Fig 5) . There was no clear association between regions' adjusted perioperative mortality for bypass and endovascular interventions.
Acute limb ischemia. Procedure volume ranged from 9 to 658 for bypasses being performed for acute limb ischemia. In hospital and 30-day mortality rates did not significantly differ between regions (0.0%-7% [P ¼ .45] and 0.0%-8% [P ¼ .40], respectively). Rates of myocardial infarction (0.0%-11%; P ¼ .004) varied significantly, but ipsilateral major amputation (0.0%-8%; P ¼ .24) did not. A Of those admitted from home.
The procedure volume ranged from 7 to 695 for endovascular interventions being performed for acute limb ischemia. In-hospital mortality did not significantly differ (0.0%-7%; P ¼ .06) but 30-day mortality did (0.0%-7%; P ¼ .01). Technically unsuccessful revascularizations ranged from 0.0% to 29% (P ¼ .001).
One-year outcomes
We excluded 1660 (10%) secondary bypasses and 8288 (23%) subsequent endovascular interventions from 1-year analysis and then selected only patients whose procedures were performed 9 months or more before date of data extraction (leaving 9158 or 77% bypasses and 17,123 or 73% endovascular procedures). Of this group, 751 (7.7%; regional range, 3%-12%; P < .001) patients undergoing bypass and 1845 (9.6%; regional range, 6%-13%; P < .001) patients undergoing endovascular intervention were clinically high risk. One region had no eligible long-term follow-up data and was excluded from the analysis. Procedure volume in the remaining 15 regions ranged from 63 to 3679 patients for bypass and 207 to 4925 for endovascular interventions. Survival data were complete, but of those eligible for 1-year follow-up, 51% had follow-up amputation data in the bypass cohort and 42% in the endovascular cohort at 1 year. On subanalysis, including only centers with >50% 1-year follow-up reporting, 57 centers of a total 134 were included for bypass operations and 38 of 134 total for endovascular intervention. Of Elective cases only. Amp, Amputation; MI, myocardial infarction; OR, operating room; SSI, surgical site infection.
Fig 4. Perioperative outcomes after endovascular intervention for critical limb-threatening ischemia (CLI). All variation significantly different (P < .05).
A Of those admitted from home.
Claudication. After bypass for claudication, there was no significant difference in 1-year survival (95%-100%; P ¼ .57; Fig 6) or AFS (91%-100%; P ¼ .16). For patients undergoing lower extremity endovascular interventions for claudication, there was significant variation between regions in 1-year survival (92%-100%; P < .001) and AFS (89%-100%; P < .001). On subanalysis, only including centers with >50% 1-year follow-up, there was no significant variation between regions for AFS after bypass (89%-100%; P ¼ .12); however, there still was after endovascular intervention (93%-100%; P ¼ .002) for claudication.
CLI. For patients undergoing infrainguinal bypass for CLI, there was significant variation between regions in 1-year survival (85%-94%; P < .001) and AFS (73%-91%; P ¼ .01). After excluding clinically high risk patients, variation in 1-year survival (87%-94%; P ¼ .001) and AFS (79%-93%; P ¼ .04) remained significant. Clinically high risk patients' 1-year survival and AFS did not vary significantly (73%-86% [P ¼ .12]; 68%-86% [P ¼ .23]), although sample size limited this analysis (region range, 31-2447 patients).
Patients undergoing lower extremity endovascular interventions for CLI had significant variation between regions in 1-year survival (77%-96%; P < .001) and AFS (68%-86%; P ¼ .001). One-year survival and AFS continued to vary significantly in patients who were not clinically high risk (81%-97% [P < .001]; 61%-84% [P ¼ .001]) but did not in clinically high risk patients (63%-95% [P < .001]; 57%-92% [P ¼ .29]).
The 30-day and 1-year mortality rates for clinically high risk patients were high (bypass, 5.4% and 20%; endovascular, 4% and 22%), with relatively low 1-year major amputation rates (bypass, 6.7%; endovascular, 3.3%). On subanalysis for patients with CLI, for centers with >50% 1-year follow-up, AFS after bypass was not significantly different between regions (73%-92%; P ¼ .06), but it was after endovascular intervention (59%-81%; P ¼ .046). 
DISCUSSION
This analysis highlights the degree of variation in both perioperative and 1-year outcomes among the 16 regions of the VQI for the treatment of lower extremity vascular disease. Accepted benchmarks for outcomes after PAD revascularization are less well defined than are the guidelines for selection of patients, given the broad spectrum of disease severity and patient factors. However, there are several 1-year outcomes after treatment for claudication that have been proposed for measuring effective clinical care, which include AFS and documented assessment of patency (Table) . 7, 15 For CLI, OPGs have been proposed to evaluate catheter-based intervention efficacy and to offer potential benchmarks for outcomes after both bypass and endovascular procedures, and they include both 30-day and 1-year end points. 8, 12, 16, 17 The Physician Quality Reporting System measures, which are in use currently for performance reporting and financial incentives, focus on treatment of intermittent claudication and measure 1-year AFS, surveillance for patency, and medications at discharge. We previously reported on the significant variation in prescribing of antiplatelet and statin medications at discharge across the VQI. 10 In this analysis, we found significant variation between regions in 1-year survival and AFS after endovascular intervention but not bypass for claudication, although this lack of significance may well be due to differences in sample size. Furthermore, prior work has established that few patients with claudication go on to develop CLI, and therefore the decision to operate on claudication should be predicated on a very low probability of mortality. 13, 15, 18 We found low 30-day mortality rates after both bypass and endovascular intervention across all regions. Any variation across regions in this lowrisk group warrants further research. The SVS OPGs have a suggested target rate of 80% for 1-year survival in patients with CLI who are not clinically high risk. In our analysis, all regions met this goal after bypass and endovascular interventions for CLI, after risk stratification for age and tissue loss. 8 There was still significant variation across regions, however, and it remains unclear what proportion of these patients underwent endovascular intervention because they were too high risk for bypass or because of the physician's or patient's preference, but this warrants further analysis. The proposed OPG for 1-year AFS in CLI of 71% was met by all regions after bypass but not endovascular intervention, even in the non-high-risk patients; although age and tissue loss are important determinants of survival, multiple other patient factors are likely to contribute. Given the percentage of missing amputation data, we refrain from making further conclusions but think that variation in both survival and AFS warrants further investigation, with attempts to completely adjust for patient differences. Furthermore, for high-risk patients with limited life expectancy, the potential benefit of a minimally invasive procedure to provide limb salvage for the remainder of their life should be weighed against setting a threshold for appropriate outcomes in this population. In our analysis, there was a relatively low major amputation rate in clinically high risk patients, with the majority surviving 30 days after their intervention, which may mean the intervention was worthwhile and potentially made the difference in preventing a major amputation before death. Our study reports significant variation between regions in in-hospital ipsilateral major amputation after elective bypass for CLI, highlighting a potential area for quality improvement. Although not directly comparable to the SVS OPG of 3% for 30-day major amputation, we did find rates of in-hospital major amputation after elective bypass for CLI as high as 4.3%. The SVS OPGs do not set a target for 30-day mortality but do use a rate of 2.7% for the calculation of major adverse cardiovascular event targets, and we found all regions near or below this rate after endovascular intervention but found 30-day mortality rates as high as 6% after bypass.
There have been growing data to support the association of blood transfusions with adverse outcomes, including SSIs. 19, 20 We found significant variation between regions in transfusion rates after bypass for claudication and CLI. Given the strong randomized controlled trial data regarding transfusion thresholds in general and the high cardiovascular risk of the vascular population, an argument can be made to attempt to standardize transfusion thresholds in the postoperative care of these patients. 13, 21, 22 SSIs after bypass are a major indication for perioperative readmission. 23 The VQI has identified chlorhexidine preparation as an important quality metric for reduction of SSIs, which we previously reported to significantly vary, but there are likely to be additional factors contributing to SSI, and the VQI offers a unique opportunity to identify high-performing regions and centers to further study what best practice should be in the bypass patient and to reduce the variation currently reported. 10, 19, 24, 25 In addition, 30-day major adverse cardiovascular events have been stressed by major professional societies as an important end point in the vascular population. 8 The VQI reports in-hospital stroke and myocardial infarction events after bypass and so could not be directly compared with the SVS OPGs, but we report significant variation between regions in postoperative myocardial infarctions among patients with CLI undergoing bypass. Patient selection, medications, intraoperative complications, and postoperative care are likely all contributing to myocardial infarctions postoperatively, and efforts should be focused on quantifying the risk associated with each of these factors. Limitations of this study include an inability to analyze all 30-day and 1-year OPGs because most data in the VQI are collected at the time of discharge and only limited postdischarge outcomes are collected, with survival being the most reliable. For this reason, we limited the postdischarge end points focused on in this analysis to survival and AFS. It is not possible in this registry to distinguish reporting of death from the Social Security Death Index and from the actual hospital site, and so reporting rates from each hospital on survival could not be factored into this analysis. In addition, amputation data were missing in approximately half of the eligible patients, and so these results should be further verified within each region as longterm follow-up data reporting improves. We also ran a subanalysis for AFS including only centers with >50% long-term follow-up reporting to account for this limitation. Furthermore, the authors for the SVS OPGs recommend caution in using their benchmarks to compare nonrandomized populations, given the inability to control for all patient selection factors with such study designs, and also state that the target rates are meant for assessment of candidacy for an entry-level device. This study focuses on variation for these end points among VQI regions and uses the OPG as a reference point, but one should not make conclusions about quality of care being delivered from this analysis as such a judgment would require appropriate risk adjustment. However, we do think this analysis can serve as a step toward risk-adjusted benchmarks agreed on by the professional societies who primarily treat PAD. We do not have enough data on volume to factor this into analysis of regional outcomes, particularly because this is a growing registry and therefore we cannot tell the true volume of each hospital and surgeon. Also, this analysis reports unadjusted outcomes because it is meant to serve as a description of current practice across the country and as a starting point for identifying projects for quality improvement.
CONCLUSIONS
Significant variation between regions exists in outcomes after revascularization for PAD and should prompt further research into appropriate patient and treatment selection. This unadjusted analysis represents a real-world assessment of variation in performance between VQI regions and, it is hoped, will act as a catalyst for future quality improvement projects. 
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